1h-Indol-5-ol,2-[4-amino-1-(1-methylethyl)-1h-pyrazolo[4,3-c]pyridin-3-yl]- | 1186647-66-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 1h-Indol-5-ol,2-[4-amino-1-(1-methylethyl)-1h-pyrazolo[4,3-c]pyridin-3-yl]-
• 英文别名: 2-(4-amino-1-propan-2-ylpyrazolo[4,3-c]pyridin-3-yl)-1H-indol-5-ol
• CAS: 1186647-66-4
• 化学式: C₁₇H₁₇N₅O
• 分子量: 307.35
• InChiKey: ORWRYWILMHHJPC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  23
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  92.8
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• [EN] COMBINATION OF KINASE INHIBITORS AND USES THEREOF<br/>[FR] COMBINAISON D'INHIBITEURS DE KINASE ET SES UTILISATIONS
  申请人：INTELLIKINE LLC

  公开号：WO2014151147A1

  公开（公告）日：2014-09-25

  The present invention provides for a method for treating a disease condition associated with PI3-kinase a and/or mTOR in a subject. In another aspect, the invention provides for a method for treating a disease condition associated with PI3-kinase a and/or mTOR in a subject. In yet another aspect, a method of inhibiting phosphorylation of both Akt (S473) and Akt (T308) in a cell is set forth. The present invention also provides a pharmaceutical kit effective for treating a disease condition associated with PI3 -kinase α and/or mTOR in a subject.

  本发明提供了一种治疗与受体内PI3-激酶α和/或mTOR相关的疾病状况的方法。另一方面，该发明提供了一种治疗与受体内PI3-激酶α和/或mTOR相关的疾病状况的方法。在另一个方面，提出了一种抑制细胞内Akt（S473）和Akt（T308）磷酸化的方法。本发明还提供了一种有效治疗与受体内PI3-激酶α和/或mTOR相关的疾病状况的药物套装。
• Combination pharmaceutical compositions and uses thereof
  申请人：Intellikine LLC

  公开号：US10172858B2

  公开（公告）日：2019-01-08

  The present invention provides for methods and pharmaceutical compositions for treating proliferative disorders. In one aspect, the method comprises administration of two cell-cycle suppressors having a synergistic effect. In another aspect, two cell-cycle suppressors having a synergistic effect are provided in a pharmaceutical composition.

  本发明提供了治疗增殖性疾病的方法和药物组合物。一方面，该方法包括服用两种具有协同作用的细胞周期抑制剂。另一方面，在药物组合物中提供两种具有协同作用的细胞周期抑制剂。
• KINASE INHIBITORS AND METHODS OF USE
  申请人：Intellikine, LLC

  公开号：EP2252293B1

  公开（公告）日：2018-06-27
• COMBINATION OF CATALYTIC MTORC 1/2 INHIBITORS AND SELECTIVE INHIBITORS OF AURORA A KINASE
  申请人：Millennium Pharmaceuticals, Inc.

  公开号：EP2976086B1

  公开（公告）日：2020-10-14
• COMBINATION OF KINASE INHIBITORS AND USES THEREOF
  申请人：Ren Pingda

  公开号：US20120294930A1

  公开（公告）日：2012-11-22

  The present invention provides for a method for treating a disease condition associated with PI3-kinase α and/or mTOR in a subject. In another aspect, the invention provides for a method for treating a disease condition associated with PI3-kinase α and/or mTOR in a subject. In yet another aspect, a method of inhibiting phosphorylation of both Akt (S473) and Akt (T308) in a cell is set forth.